Good morning everyone, and a warm welcome to our Quarter 4 results call planned for the coming 30 minutes. With me today, I also have our CFO, Yilmaz Mahshid; Henrik Krook, Vice President, Commercial Operations; Anny Bedard, President, North America; and Karl Hård, Vice President, Investor Relations. Let us turn our attention to the topics being covered today. But first, let me start by saying that I'm incredibly pleased with the past year and also the deliverables post the period.
The completion of the US rolling NDA in January 2026 for Emcitate, on the back of a successful pre-NDA meeting and a breakthrough designation granted by the FDA, leads us to an anticipated regulatory decision in September this year.
The commercial performance showed Emcitate revenue during 2025 amounted to 62.3 Swedish million kronor and a 40% increase at constant exchange rate versus 2024. And also in Japan, where we have a license agreement with Fujimoto Pharmaceutical Corporation for the development and commercialization of tiratricol there. Fujimoto completed in December a so-called pre-application consultation for drugs with the Japanese PMDA.
The NDA in Japan is expected to utilize the existing data generated from the global Clinical Development program. Moreover, Henrik and Anny will provide an update on commercialization in Europe and launch preparations in the US. And then Yilmaz at the end will provide an update on our financial performance. But first, let me summarize. The year 2025 was historic, with very strong execution that led to a number of significant milestones delivered.
First, Emcitate was approved in EU in February as the first and only treatment for patients with MCT8 deficiency, and subsequently we initiated launch in the first country, Germany, in May 2025. In July, a breakthrough designation was granted by the FDA. The breakthrough designation was granted by the agency's review of a detailed analysis of the entire survival data set from the international Real World Cohort Study, the so-called EMC Survival Study by the Erasmus Medical Center, which demonstrated a significant and substantial improvement in survival in tiratricol treated versus untreated MCT8 deficiency patients. On the back of the breakthrough designation, FDA granted a so-called Pre-NDA meeting that took place in October with a very successful outcome. First, the NDA for Emcitate for the treatment of MCT8 deficiency will be based on currently available data, which means data included from Triac Trial I, Triac Trial II, ReTRIACt, the EMC Cohort Study, the EMC Survival Study, as well as the U.S. Expanded Access Program. So all in all, a very large and robust data set considering an ultra rare condition.
Second, the FDA agreed that in NDA submission data from the ReTRIACt study will complement the existing data from the EMC Survival Study and the other clinical components I just referred to. Therefore, the ReTRIACt study was closed and data accrued was included in the NDA as agreed with the FDA. And lastly, the agency agreed to submit a rolling New Drug Application for Emcitate.
So in November we announced the positive results from the ReTRIACt study. The results demonstrate a statistically significant difference in the rate of change in serum T3 in patients randomized to withdraw, i.e. Placebo versus in patients continuing therapy. Subsequent to that, we initiated the rolling NDA for Emcitate on the 19th of December with the submission of the preclinical and CMC sections, and completed the NDA on the 29th of January this year by submitting the clinical sections. Looking ahead, the FDA is now expected to validate within 60 days whether the NDA dossier is complete. Since Emcitate has both Fast Track Designation and Breakthrough Therapy Designation, we have requested a priority review which, if granted, would result in the FDA's review being completed within six months after the validation period, and hence a regulatory decision is expected in September 2026. So with that, I will hand over to Henrik for an update on commercialization in Europe. Hendrik, over to you. Thank you, Nicklas.